In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 90 for your search:

Drug:  pegfilgrastim
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase IV Randomized Study of Filgrastim (G-CSF) or Pegfilgrastim as Secondary Prophylaxis Versus Conservative Management of Chemotherapy-Induced Neutropenia for Maintenance of Chemotherapy in Women With Early Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase IV
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: ACCOG-SCTN-BR0101, SCTN-BR0101, EU-20143, NCT00030758

LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2006-003750-23, LINFOTARGAM, NCT00466258

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 60
Sponsor: Other
Protocol IDs: AMLSG07-04, NCT00151242

Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel

Phase: Phase III, Phase II
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NEUGR-002, NCT00837265

GCPGC in Chemotherapy-induced Neutropenia

Phase: Phase III, Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GCPGC P2/3, NCT01328938

Phase III Pilot Randomized Study of Filgrastim-SD/01 Versus Filgrastim (G-CSF) With Concurrent Chemotherapy in Patients With Newly Diagnosed Sarcoma (Closed to Accrual as of 5/26/2009)

Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 25 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-00-C-0092, AMGEN-20000124, NCT00020137

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000068020, GOG-0184, ECOG-G0184, RTOG-EN0130, NCT00006011

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 60
Sponsor: Other
Protocol IDs: CDR0000258125, EORTC-20012, GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, hd8, NCT00049595

Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000302584, EORTC-62012, NCT00061984

10.

Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000334899, SWOG-S0221, S0221, NCT00070564

11.

Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000463447, ICR-TACT2, EU-205114, EUDRACT-2004-000066-13, MREC-04/MRE00/88, ISRCTN68068041, NCT00301925

12.

Phase III Randomized Study of Adjuvant Therapy Comprising Epirubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With Versus Without Fluorouracil and/or Pegfilgrastim in Women With Node-Positive Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: GIM-2, EU-20681, NCT00433420

13.

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 60
Sponsor: Other
Protocol IDs: IIL-DLCL04, EudraCT number 2007-000275-42, NCT00499018

14.

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: NSABP B-46-I, USOR 07132, NCT00887536

15.

PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20080259, NCT00911170

16.

Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NEUGR-003, NCT01126190

17.

A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: HHPG-19K -III-01, NCT01611051

18.

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: MA22, CAN-NCIC-MA22, CDR0000316237, NCT00066443

19.

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02600, 12975A, N01CM62201, CDR0000371904, UCCRC-12975A, 6243, NCI-6243, NCT00086944

20.

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00239, 06-12-487, CDR0000543434, N01CM62202, N01CM62204, NYCC-06-12-487, 7868, NCT00470301

21.

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 05-077, MSKCC-05077, NCT00546377

22.

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PSOC 2302, NCI-2010-00870, 6632, FHCRC-IR-6632, NCT00601718

23.

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: PSOC 2001, AVENTIS-PSOC-2001, PSOC-IRB-5689, CDR0000441312, NCT00217529

24.

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: CDR0000067154, COG-D9802, IRS-D9802, CCG-D9802, POG-D9802, NCT00003955

25.

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 272-99, P30CA036727, UNMC-272-99, AMGEN-990117, CWRU-AMGN-1499, UCLA-9906080, NCI-G99-1648, NCT00004192

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map